Evotec (NASDAQ:EVO) reported quarterly losses of €(1.11) per share which missed the analyst consensus estimate of €(0.75) by 48 percent. This is a 136.17 percent decrease over losses of €(0.47) per share from the same period last year. The company reported quarterly sales of € 797.00 million which missed the analyst consensus estimate of € 801.87 million by 0.61 percent.